SCHEMBL6351016

SCHEMBL6351016

O=C1Nc2ccc(O)cc2/C1=C1\C=Cc2ccccc2N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
EGFR P00533 1/20 0.43
PDPK1 O15530 6/20 0.41
PDGFRB P09619 2/20 0.41
KDR P35968 2/20 0.41
PDGFRA P16234 2/20 0.41
FLT1 P17948 1/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
PLK4 O00444 2/20 0.40
PLK1 P53350 2/20 0.40
RET P07949 1/20 0.40
FLT3 P36888 1/20 0.40
MAP3K7 O43318 1/20 0.38
TAB1 Q15750 1/20 0.38
CHEK1 O14757 1/20 0.37
ACVR1 Q04771 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6351020 1.00 NTRK1 (0.46) NTRK1CCNA2CDK2CCNA1EGFR
SCHEMBL6358112 0.84 MAPT (0.50) NTRK1CCNA2CDK2CCNA1KDR
SCHEMBL6279537 0.84 MAPT (0.50) NTRK1CCNA2CDK2CCNA1KDR
SCHEMBL6351562 0.83 TLK2 (0.44) CDK2PDPK1PDGFRBKDRMAPT
SCHEMBL6351566 0.83 TLK2 (0.44) CDK2PDPK1PDGFRBKDRMAPT
SCHEMBL6355206 0.80 MAPT (0.43) PDGFRBPDGFRAMAPTGAAACVR1
SCHEMBL6355203 0.80 MAPT (0.43) PDGFRBPDGFRAMAPTGAAACVR1
SCHEMBL6355564 0.79 NEK2 (0.48) PDPK1MAPTGAAMAP3K7TAB1
SCHEMBL6355565 0.79 NEK2 (0.48) PDPK1MAPTGAAMAP3K7TAB1
SCHEMBL6351678 0.78 MAOA (0.62) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 NTRK1 573/4885CCNA2 632/4885CDK2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.